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Abstract
Objectives Denosumab, a human monoclonal antibody
(mAb) that neutralizes receptor activator for nuclear factor
κB ligand (RANKL), is associated with osteonecrosis of the
jaw. However, the effect of denosumab on oral wounds is
unclear. The aim was to determine the effect of anti-RANKL
mAb on oral wounds and bone marrow.
Materials and methods The direct effect of the mAb on fibro-
blasts, macrophages, and osteoclasts were assessed in vitro.
In vivo, mouse anti-RANKL mAb was administered to mice
for 9 weeks prior to palatal bone denudation surgery. Mice
were euthanized 3 weeks post-surgery, and wound healing
was histomorphometrically analyzed. Long bones were
assessed using micro-computed tomography, quantitative
real-time polymerase chain reaction, and flow cytometry.
Results The mAb had no effect on macrophages and fibro-
blasts but significantly suppressed osteoclast proliferation
in vitro. The mAb treatment significantly increased bone mass
by suppressing osteoclasts in vivo. The expression of pro-
osteoclastic genes was promoted in the bone marrow of the
mAb-administered animals. Consistently, the mAb signifi-
cantly induced the development of tartrate-resistant acid phos-
phatase (TRAP)-positive mononuclear cells (MNCs) but not
osteoclasts in bone marrow. The mAb treatment had no effect
on gross healing of the palatal wounds. However, significant
inflammation was retained in the connective tissue facing the
once denuded bone surface.
Conclusions Repair of the damaged palate was delayed, and
significant inflammation was sustained in the connective tis-
sue by anti-RANKL mAb treatment.
Clinical relevance Denosumab impairs osteoclastic bone re-
pair. Care should be exercised to minimize osseous trauma
when invasive procedures are performed on patients taking
denosumab.
Keywords Antiresorptives . Mouse anti-RANKL
monoclonal antibody .Wound healing . Inflammation .
TRAP-positive mononuclear cells
Introduction
Osteoclasts are multinucleated bone-resorbing cells derived
from the myeloid lineage that play critical roles in skeletal
growth/remodeling, hematopoiesis, bone fracture healing,
and bone diseases such as osteoporosis, Paget’s disease of
bone, and multiple myeloma. It has been demonstrated that
long-term suppression of osteoclasts by bisphosphonate treat-
ment increases non-attached osteoclasts in bone marrow, i.e.,
cells are not directly on bone surfaces [1–3]. Similarly, we
have found that long-term bisphosphonate treatment is asso-
ciated with increased numbers of tartrate-resistant acid phos-
phatase (TRAP)-positive mononuclear cells (MNC) in mouse
bone marrow [4]. It was further demonstrated that
antiresorptive treatment with bisphosphonates has a negative
impact on oral wound healing; bisphosphonate treatment in-
creases inflammatory cell infiltration and reduces collagen
apposition in wounds [5, 6]. Thus, osteoclast suppression by
potent bisphosphonates alters the cellular environment in bone
marrow as well as in oral wound healing. However, whether
* Junro Yamashita
yamashit@umich.edu
1 Department of Applied Prosthodontics, Graduate School of
Biomedical Sciences, Nagasaki University, 1-7-1, Sakamoto,
Nagasaki, Nagasaki 852-8588, Japan
2 Department of Biologic and Materials Sciences, Prosthodontic
Division, School of Dentistry, University of Michigan, 1011 North
University Ave., Ann Arbor, MI 48109, USA
Clin Oral Invest (2016) 20:727–736
DOI 10.1007/s00784-015-1550-0
these findings are specifically linked to osteoclast suppression
or bisphosphonates themselves is unclear. If increased
TRAP(+)MNCs and altered oral wound healing are associated
with osteoclast suppression, not specifically bisphosphonates
themselves, then similar observations should be found when
another class of potent antiresorptives, denosumab, is used.
Denosumab is a humanmonoclonal antibody to the receptor
activator of nuclear factor-κB ligand (RANKL) that potently
suppresses bone resorption by targeting osteoclasts [7]. It has
been approved for the treatment of bone diseases such as oste-
oporosis, metastatic bone diseases, and multiple myeloma in
the USA and other countries [7, 8]. Denosumab is a potent
antiresorptive with a different mechanism of action from
bisphosphonates. Bisphosphonates bind to bone mineral. Dur-
ing bone resorption, osteoclasts take up bisphosphonates to-
gether with bone mineral. Internalized bisphosphonates induce
osteoclast apoptosis, thereby inhibiting further resorption [9].
Thus, bisphosphonates target active bone-resorbing osteoclasts.
On the other hand, denosumab attaches to RANKL and hinders
its ability to bind to its receptor, RANK, which is expressed on
mature osteoclasts and their precursors [10]. Since RANKL–
RANK binding is essential for osteoclast differentiation and
survival, the disruption of this binding profoundly hinders os-
teoclast development, hence bone resorption. Thus, denosumab
targets not only active bone-resorbing osteoclasts but pre-
osteoclasts as well. Although the mechanism of the
antiresorptive action is distinct between denosumab and
bisphosphonates as described above, the literature indicates that
denosumab treatment is also associated with the development
of medication-related osteonecrosis of the jaw (MRONJ) which
is a rare complication typically related to bisphosphonates [11,
12]. This suggests that denosumab and bisphosphonates may
share a mechanism that contributes to the development of
MRONJ. In this study, we hypothesized that denosumab treat-
ment increases TRAP(+) MNCs in bone marrow and oral
wounds. To test the hypothesis, mice were treated with mouse
monoclonal antibody to RANKL (anti-RANKL mAb). The
effects of the anti-RANKL mAb treatment on bone marrow
and oral wound healing were examined.
Materials and methods
Animals, injections, and oral wounds
Fourteen C57BL/6 J mice (9-week-old) were obtained from
the Jackson Laboratory (Bar Harbor, ME, USA) and main-
tained in a temperature-controlled room with 12 h/12 h light/
dark cycles. Mice were allowed to access water and standard
diet ad libitum. A mouse anti-RANKL mAb (OYC Americas,
Andover, MA, USA) was subcutaneously injected to half of
the mice at 5 mg/kg once every 3 weeks for 9 weeks (mAb).
Saline was injected to the remaining half as vehicle control
(VC) (Fig. 1a). The experimental protocol was approved, and
animals were treated in accordance with the guideline of the
University Committee on Use and Care of Animals. Oral
wounds were created at 9 weeks after the initiation of the
treatment. Mice received general anesthesia (ketamine–
xylazine cocktail), and the palate next to the first molar (M1)
was denuded by excising a portion of the mucosa and under-
lying periosteum (Fig. 1b). The contralateral intact side served
as an internal control. Mice were euthanized by CO2 asphyx-
iation at 3 weeks after surgery.
Histomorphometric analysis
At sacrifice, maxillae and left tibiae were harvested, fixed in
10 % formalin, and decalcified in 10 % ethylenediaminetetra-
acetic acid. The decalcified maxillae and tibiae were proc-
essed for paraffin sections. TRAP staining was performed to
identify osteoclasts and TRAP(+) MNCs using a commercial
kit (386A, Sigma-Aldrich, St. Louis, MO, USA). TRAP-
stained sections were photomicrographed, and osteoclasts on
the bone surfaces, non-attached osteoclasts, and TRAP(+)
MNCs within 100 μm of the bone surfaces were
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Fig. 1 Experimental design and palatal wounds. Mouse anti-RANKL
mAb (mAb) and saline (vehicle control, VC) injections were performed
subcutaneously once every 3 weeks for 9 weeks. The palate was denuded
at 9 weeks and left as an open wound.Mice were euthanized 3weeks after
the surgery (a). The denuded palate is shown. The area was surrounded
by the M1, rugae, and great palatine canal (b)
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histomorphometrically quantified using Image-Pro Plus (Me-
dia Cyberrnetics, Bethesda, MD, USA). Masson’s trichrome
staining was conducted using a commercial kit (HT15, Sigma-
Aldrich, USA) to assess inflammation. Inflammatory cell in-
filtration was quantified in the palatal connective tissue facing
towards the once exposed bone surfaces. Empty osteocyte
lacunae were enumerated in the bone area exposed to the oral
environment after denuding. Epithelial thickness was mea-
sured in the healing wounds. The contralateral intact side
was examined for the same parameters as well.
Microcomputed tomography
The right femur was fixed in 10 % formalin and subjected to
trabecular bone analysis in microcomputed tomography
(microCT) (μCT-100; Scanco Medical, Bruttisellen,
Switzerland) at 10-μm voxel resolution with an energy level
of 70 kV. The distal metaphysis was scanned for 1.5 mm
proximal to the growth plate. Reconstructed images were seg-
mented by the semi-manual contouring method and analyzed
for the trabecular bone structure using the built-in Scanco
software.
Flow cytometry
Fresh bone marrow was harvested from the left femur,
and MNCs were isolated after red blood cell lysis of the
bone marrow using ACK buffer (Invitrogen). MNCs
(1×106) were incubated with phycoerythrin (PE) anti-
mouse CD3e (clone: 145-2C11) and γδTCR (clone:
GL3). PE Hamster IgG was used for isotype controls.
Cell analysis of CD3(+) and γδTCR(+) was performed
using the C6 Flow Cytometer (Accuri, Ann Arbor, MI, USA).
All antibodies for flow cytometry were purchased from
eBiosciences (San Diego, CA, USA).
Serum calcium
Serum was isolated from harvested blood at euthanasia and
kept at −80 °C until use. Serum calcium levels were assessed
using a commercially available calcium assay kit (Pointe Sci-
entific, Canton, MI, USA).
In vitro assays
Bone marrow cells were isolated from the right tibiae and
cultured overnight in DMEM supplemented with 10 % fetal
bovine serum (FBS), 100 U/mL of penicillin, and 100 μg/mL
of streptomycin. Suspension cells were then collected, plated
at 2.5×105 cells/cm2, and treated with 50 ng/mL of macro-
phage colony-stimulating factor (M-CSF; Peprotech, Rocky
Hill, NJ, USA) every 3 days to induce and maintain macro-
phages. Macrophages were plated at 2.0×104 cells/cm2 and
cultured in the supplemented DMEM containing M-CSF
(50 ng/mL). The anti-RANKL mAb treatment (0, 1, or
10μg/mL) was initiated at day 0. At day 3, either cell counting
or RNA extraction was performed. For osteoclast cultures,
macrophages were plated at 2.0×104 cells/cm2 in the supple-
mented DMEMwithM-CSF (50 ng/mL) and RANKL (50 ng/
mL) (Peprotech). Medium was replaced every 2 days. At day
5, osteoclast cultures were treated with the anti-RANKL mAb
(0, 1, or 10μg/mL) for 24 h. At day 6, either TRAP staining or
RNA extraction was performed. Small pieces of gingiva were
harvested from mice, and organ cultures were performed to
obtain gingival fibroblasts. Fibroblasts were plated at 2.0×
104 cells/cm2 and cultured in supplemented DMEM con-
taining the mouse anti-RANKL mAb (0, 1, or 10 μg/mL).
Medium was replaced every 2 days. Cells were enumerated
at days 2, 4, and 6. In addition, total RNA was extracted
using the phenol/chloroform method. RNA was stored at
−80 °C until use.
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Quantitative real-time polymerase chain reaction
Fresh bone marrow was isolated from the right tibia directly
into TRIZOL (Invitrogen, Grand Island, NY, USA) using a
centrifugation method [5]. Total RNA was extracted and
stored at −80 °C until use. Bone marrow RNA as well as total
RNA from the in vitro experiments was analyzed for gene
expression. First-strand cDNAwas synthesized using the Su-
perScript First-Strand system (Invitrogen). Quantitative real-
time polymerase chain reaction (qPCR) was performed using
an iCycler IQ (BioRad, Hercules, CA, USA) with SYBR
green (Invitrogen). The samples were run in triplicate, and
results were normalized by glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) expression. Relative quantification of
data generated using this system was performed using the
standard curve method. Primer sets used were GAPDH, C-
fms, RANK, RANKL, CTSK, Dcstamp, Bcl2, Bax, Bak, Bim,
and Bad (Table 1).
Statistical analysis
All data sets were tested for equality of variances. Independent
t-test and one-way analysis of variance (ANOVA) for para-
metric data and Kruskal–Wallis test for non-parametric data
were performed using SYSTAT (Systat Software, Chicago,
IL, USA). An α-level of 0.05 was used. Results are presented
as mean±SEM.
Results
Anti-RANKL mAb suppressed osteoclasts but not
macrophages and gingival fibroblasts in vitro
The anti-RANKL mAb treatment showed no effects on mac-
rophage numbers (Fig. 2a), and consistently, no apoptosis-
associated genes were regulated by the mAb treatment
(Fig. 3a). The expression of RANKL was significantly upreg-
ulated at the RNA level by the mAb treatment (Fig. 3a). The
anti-RANKL mAb treatment significantly suppressed osteo-
clasts numbers as expected (Fig. 2b). Significantly more
TRAP(+) MNCs were observed by the treatment (Fig. 2c).
At the RNA level, the expression of osteoclast marker genes
including RANK, RANKL, CTSK, and Dcstamp were signifi-
cantly downregulated, but C-fms was significantly upregulat-
ed by the mAb treatment. The expression of pro-apoptotic
genes including Bad, Bax, and Bim were significantly upreg-
ulated as expected (Fig. 3b). Primary gingival fibroblasts were
treated with the anti-RANKL mAb and enumerated over
6 days. The treatment had no effect on cell numbers
(Fig. 2d). The expression of pro-apoptotic genes (Bak, Bad,
Bax, and Bim) and RANKL was not regulated by the mAb
treatment in gingival fibroblasts (Fig. 3c).
Anti-RANKL mAb suppressed osteoclasts but increased
TRAP(+) MNCs in vivo
To confirm that anti-RANKL mAb had the expected
antiresorptive effect, the distal femurs were assessed using
microCT. The anti-RANKL mAb treatment resulted in a sig-



















































































Fig. 2 Osteoclast suppression by anti-RANKL mAb in vitro. Primary
macrophages were expanded in bone marrow suspension cells byM-CSF
treatment. Macrophages were treated with 0, 1, or 10 μg/mL of the anti-
RANKL mAb for 3 days and cell numbers (a) were counted.
Osteoclastogenesis was performed by stimulating macrophages with M-
CSF and RANKL. Osteoclast cultures at day 5 were treated with the anti-
RANKL mAb for 24 h and stained for TRAP expression. Average
osteoclast numbers (b) and TRAP(+) macrophages (c) were plotted.
Primary gingival fibroblasts were isolated from small pieces of gingiva
and expanded. Gingival fibroblasts were cultured for 6 dayswith themAb
treatment every 2 days. Cells were enumerated and plotted (d). All assays
were triplicated. *p<0.05, **p<0.01, ***p<0.001
Fig. 3 Anti-RANKL mAb treatment upregulated pro-apoptotic genes in
osteoclasts in vitro. Primary macrophages were expanded from bone
marrow suspension cells by M-CSF treatment. Macrophages were
treated with 0, 1, or 10 μg/mL of anti-RANKL mAb for 3 days. Total
RNA was extracted, and cDNA was prepared. The expression of
osteoclast- and apoptosis-related genes was assessed using qPCR (a).
Osteoclastogenesis was performed by stimulating macrophages with M-
CSF and RANKL. Osteoclast cultures at day 5 were treated with anti-
RANKL mAb for 24 h, total RNA was extracted, and cDNA was
prepared. The expression of osteoclast- and apoptosis-related genes was
assessed using qPCR (b). Primary gingival fibroblasts were cultured for
6 days with anti-RANKL mAb treatment every 2 days. At day 6, total
RNAwas extracted and cDNAwas prepared. The expression of RANKL
and apoptosis-related genes was assessed using qPCR (c). All assayswere
triplicated. *p<0.05, **p<0.01, ***p<0.001
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mineral density (BMD) compared to VC (Fig. 4a–c). Such an
increase in bone mass in the mAb-treated animals was char-
acterized by significantly increased numbers and thickness of
trabecular bone and decreased trabecular separation (Fig. 4d–
f). Histomorphometric analysis of TRAP-stained sections re-
vealed significantly smaller osteoclast surfaces and reduced
osteoclast numbers in the mAb-treated animals vs. VC
(Fig. 4g–i), indicating that osteoclast suppression contributed
to the increased bone mass observed in the mAb-treated ani-
mals. Furthermore, the mAb treatment significantly increased
TRAP(+) MNCs in bone marrow compared to VC (Fig. 4j).
The TRAP(+) MNCs were predominantly found near but not
on the trabecular bone surfaces.
Altered gene expression in bone marrow by anti-RANKL
mAb
The expression of genes associated with osteoclasts and apo-
ptosis were assessed at the RNA level by qPCR. Anti-
RANKL mAb treatment significantly upregulated pro-
osteoclast genes including C-fms, RANK, and RANKL in bone
marrow (Fig. 5a–c). However, the expression of osteoclast
marker genes including CTSK and Dcstamp were not regulat-
ed by the mAb treatment (Fig. 5d, e). The mAb treatment had
no effect on the expression of anti-apoptotic gene Bcl2 and
pro-apoptotic genes Bak and Bad (Fig. 5f–h). However, pro-
apoptotic genes, Bax and Bim, were significantly upregulated
by anti-RANKLmAb compared to vehicle control (Fig. 5i, j).
Since T cells are known to express RANKL, the effect of
the anti-RANKL mAb treatment on the T cell population in
the bonemarrowwas assessed. A pan Tcell marker, CD3, was
used via flow cytometry, and positive cells were significantly
increased by the anti-RANKL mAb treatment (Fig. 6a). Ad-
ditionally, a proportional significant increase in γδTCR(+)
cells (a distinct small subset of T cells) was noted in the
mAb group vs. VC (Fig. 6b). Despite the osteoclast suppres-
sion by anti-RANKL mAb, there were no differences in the
serum calcium level between the groups (Fig. 6c).
Anti-RANKL mAb delays oral wound healing
Histomorphometric analyses were performed to determine
whether the anti-RANKL mAb treatment altered oral wound
healing after the palate denudation. The assessment of TRAP-
stained sections revealed that the anti-RANKL mAb treat-
ment significantly suppressed osteoclasts on the once denud-
ed palatal surfaces compared to VC, while in the contralateral
intact side, osteoclasts were rarely observed regardless of the
treatment (Fig. 7a). Osteoclast surface (Oc.S/BS) and number
(Oc.N/BS) were significantly lower in the mAb group than
VC in the wounds, while no effects were noted in the contra-
lateral intact side (Fig. 7b, c). Although not significant (p=
0.058), a trend was observed that more TRAP(+) MNCs were
observed near the bone surfaces in the mAb group than VC in
healing wounds (Fig. 7d). TRAP(+) MNCs were not found in






























































































































































Fig. 4 Effect of anti-RANKL mAb in skeleton. Representative
reconstructed images of longitudinal and crosssectional femoral
microCT data (a). Bone volume fraction (BV/TV) and trabecular bone
mineral density (Tb.BMD) were significantly higher in the mAb than
VC group (b and c). Significantly higher trabecular numbers (Tb.N) (d)
and trabecular thickness (Tb.Th) (e) and significantly lower trabecular
separation (Tb.Sp) (f) were found in the mAb group vs. VC.
Representative photomicrographs of TRAP-stained bone sections. Scale
bar 50 μm (g). Asterisk indicates osteoclasts on the bone surface and
arrowheads TRAP(+) MNCs in bone marrow. Osteoclast surface
(OC.S/BS) (h) and osteoclast numbers (OC.N/BS) were significantly
lower in the mAb group than control (i). The numbers of TRAP(+)
mononuclear cells (MNCs) were significantly higher in the mAb group
than control (j). n≥7/ group; *p<0.05, **p<0.01, ***p<0.001
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representative photomicrographs of the subepithelial connec-
tive tissues in healing wounds. Larger numbers of inflamma-
tory cells (dark purple nuclei) and less collagen fibers (blue)
were observed in the healing connective tissue in the mAb
group compared to in VC (Fig. 7f). On the other hand, in the
contralateral intact side, prominent rete pegs and collagen
fibers were observed regardless of treatment. Although a sta-
tistical difference was not reached (p=0.056), a clear trend
was observed in that larger numbers of empty osteocyte la-
cunae were noted in the mAb group vs. VC in healing
wounds (Fig. 7g). In healing oral wounds, complete
epithelium coverage was observed in both groups with no
difference in thickness (Fig. 7h).
Discussion
Since denosumab has no affinity to mouse RANKL, it is a
challenge to perform an animal study to understand the
denosumab effect in bone. To overcome this difficulty,
Kostenuik et al. developed human RANKL knock-in mice,
in which denosumab can then be used and have an effect in
mice [13]. Although these human RANKL knock-in mice are
useful, they exhibit an altered skeletal phenotype from wild-
type litter mates. The knock-inmice show increased trabecular
bone with decreased osteoclasts [13]. This could be a disad-
vantage when the denosumab effects are examined in bone as
the inherent bone phenotype may affect the outcome. There-
fore, the use of an antibody which binds and neutralizes
mouse RANKL to a similar degree as denosumab in human
is ideal when the goal is to investigate the effect of RANKL
inhibition in the mouse skeleton. Furuya et al. reported that a
mouse anti-RANKLmAb which was newly developed exhib-
ited similar therapeutic effects to denosumab [14]. A single 5-
mg/kg dose of mouse anti-RANKLmAb increased bone mass
and BMD in femurs. Since the mouse anti-RANKL mAb
treatment is comparable to denosumab treatment in humans,


































































































































































































































(a) (b) (c) (d) (e)
(f) (i)(g) (j)(h)
Fig. 5 Effect of anti-RANKL mAb on bone marrow gene expression.
Gene expression was assessed in bone marrow at the RNA level. Pro-
osteoclastic genes (C-fms, RANK, and RANKL), osteoclast genes (CTSK
and Dcstamp), and apoptosis-related genes (Bcl2, Bak, Bad , Bax, and
Bim) were analyzed. Results were normalized byGAPDH expression. C-
fms (a), RANK (b), and RANKL (c) expression was significantly elevated
in the mAb group. No differences were found in the expression of CTSK
(d) andDcstamp (e) between the groups. No differences were found in the
expression of Bcl2 (f), Bak (g), and Bad (h) between the groups. The
expression of Bax (i) and Bim (j) were significantly stimulated in the



















































Fig. 6 Effect of anti-RANKL mAb on T-cells and serum calcium. The
anti-RANKL mAb treatment resulted in a significant increase in CD3(+)
T cells (a) and γδTCR(+) cells (b). No statistical differences were noted
in the serum Ca level between the groups (c). n≥7/ group; **p<0.01,
***p<0.001
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RANKL inhibition in the bone marrow environment and oral
osseous wound healing. In this study, we examined the inhib-
itory effect of mouse anti-RANKL mAb on osteoclasts
in vitro. Osteoclasts were induced by M-CSF and RANKL
from primary macrophages. When osteoclast cultures were
treated with anti-RANKL mAb, the osteoclast number signif-
icantly dropped. However, no osteoclastogenesis was dis-
turbed with the vehicle treatment. Since pro-apoptotic Bad,
Bax, and Bim were significantly upregulated in the mAb-
treated osteoclasts, the significant drop in the osteoclast num-
ber was likely due to apoptosis. We further examined whether
the anti-RANKL mAb affects macrophages and gingival fi-
broblasts and found no apoptotic effect on these cell types.
Therefore, the mouse anti-RANKL mAb was specific to oste-
oclasts as anticipated. To gauge its antiresorptive effect






















































































































































































Fig. 7 Altered oral osseous wound healing by the anti-RANKL mAb
treatment. Representative photomicrographs of TRAP-stained palatal
sections. Asterisk osteoclasts on the bone surface, white arrowhead
non-attached osteoclasts, black arrowhead TRAP(+) MNCs. TRAP(+)
cells were rarely observed in the contralateral intact side. Scale bar
50 μm (a). Anti-RANKL mAb treatment significantly suppressed
osteoclast surface (OC.S/BS) and osteoclast number (OC.N/BS)
compared to VC in the wound side, while osteoclasts were rarely
observed regardless of treatment in the contralateral intact side (a–c).
Anti-RANKL mAb treatment increased TRAP(+) MNCs in the palatal
connective tissue of the wound side compared to VC treatment (p=.058).
No TRAP(+) MNCs were detected in the contralateral intact side
regardless of treatment (d). Representative photomicrographs of
Masson’s trichrome-stained palatal sections. Scale bar 200 μm (e).
Significant polymorphonuclear neutrophil (PMN) (dark purple nuclei)
infiltration was noted in the connective tissue of the wound side in the
mAb-treated animals. No PMN infiltration was noted in the contralateral
intact side irrespective of treatment (f). The numbers of empty osteocyte
lacunae were higher in the mAb group than VC (p=0.056) in the wound
side. Empty osteocyte lacunae were barely detected in the contralateral
intact side regardless of treatment (g). No differences were found in the
thickness of the healed epithelium (h). n≥7/ group; **p<0.01,
***p<0.001
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once every 3 weeks for 9 weeks. As expected, the administra-
tion of the mAb resulted in significantly high bone mass with
suppressed osteoclasts on the bone surfaces, confirming that
mouse anti-RANKL mAb exerted sufficient antiresorptive ef-
fects in this study via osteoclast suppression.
Significant numbers of TRAP(+) MNCs were noted in the
bone marrow of mAb-treated animals. This finding is compa-
rable to our previous finding that long-term bisphosphonate
treatment stimulates the development of TRAP(+) MNCs in
bone marrow [4]. We thought that this same finding is inter-
esting since the anti-RANKL mAb and bisphosphonates are
distinct in their mechanisms of action and pharmacokinetics
except that both result in the suppression of osteoclasts.
TRAP(+) MNCs are cells in the macrophage/monocyte line-
age which are considered immediate precursors of osteoclasts
[15]. Therefore, we speculated that increased TRAP(+)MNCs
observed in this and previous studies are associated with os-
teoclast suppression. To get insight into the elevated TRAP(+)
MNCs, the expression of pro-osteoclastic, osteoclastic, and
apoptotic genes was investigated in bone marrow at the
RNA level. It was found that the anti-RANKL mAb stimulat-
ed pro-osteoclastic genes including C-fms, RANK, and
RANKL, suggesting that the bone marrow environment stim-
ulated myeloid cells to differentiate towards osteoclasts. How-
ever, as the anti-RANKL mAb showed no effect on the ex-
pression of osteoclast genes including Dcstamp and CTSK,
terminal osteoclast differentiation was not promoted. The ex-
pression of Dcstamp is required for the fusion of TRAP(+)
MNCs [16] and CTSK for matrix degradation in osteoclasts
[17]. Therefore, in the anti-RANKL mAb-treated animals, the
bone marrow environment stimulated osteoclast progenitors
to differentiate towards osteoclasts; however, this did not
translate into an increase in multinucleated osteoclasts as the
mAb treatment inhibited their differentiation and survival.
Hence, the result of the gene expression assessment is consis-
tent with the histological finding of high numbers of TRAP(+)
MNCs with suppressed osteoclasts on the bone surfaces in the
anti-RANKL mAb-treated animals. Osteoclasts are essential
cells in bone to maintain physiological skeletal homeostasis.
Insufficient osteoclast supply in bone would prompt the mar-
row environment to stimulate osteoclastogenesis. This is es-
pecially true when bone damages accumulate or calcium is in
need [18]. When the demand is met, osteoclastogenesis would
become inactive, and no strong pro-osteoclastic signals would
be generated. However, in the anti-RANKL mAb-treated an-
imals, pro-osteoclastic signals continued, likely due to unsat-
isfactory osteoclastogenesis. This might result in the accumu-
lation of TRAP(+) MNCs in the bone. Pro-apoptotic Bax and
Bim were upregulated in the anti-RANKL mAb-treated ani-
mals. This is likely a reflection of the apoptosis of residing
osteoclasts by the anti-RANKLmAb treatment [19, 20]. Since
T-cells express abundant RANKL and are therefore important
for osteoclastogenesis [21], CD3 and γδTCR(+) cells were
assessed. We found significantly high numbers of CD3 and
γδTCR(+) cells in the anti-RANKL mAb-treated animals.
Interestingly, our previous report also observed elevated
γδTCR(+) cells in animals on long-term bisphosphonate treat-
ment [4]. As γδTCR(+) cells play a role in innate immunity
[22] and elevated γδTCR(+) cells are implicated in inflamma-
tory diseases [23], osteoclast suppression could marginally
influence the immune system.
To determine the effect of the anti-RANKL mAb treat-
ment on oral osseous wound healing, a small area of the
palate was denuded, and healing was assessed in histolog-
ical sections. The contralateral intact side was used as an
internal control. No effects of anti-RANKL treatment on
TRAP(+) MNCs, the alveolar bone, and the epithelial layer
were observed in the contralateral intact side. Consistently,
the results of the in vitro assays showed that the enumera-
tion of gingival fibroblasts and macrophages, which reflects
a sum of proliferation and apoptosis, was not affected by
the mAb treatment. The mAb treatment did not cause in-
flammation in the connective tissue when no wounds were
created. On the other hand, in the wound side, significant
PMN infiltration was noted in the connective tissue of the
mAb-treated animals. Furthermore, considerably reduced
osteoclasts with an increased number of TRAP(+) MNCs
were found in the mAb-treated animals. Thus, inflammation
with suppressed osteoclasts was particularly associated with
the wounds in the anti-RANKL mAb-treated animals. The-
se observations are quite comparable to our previous obser-
vation where the bisphosphonate zoledronic acid was ad-
ministered to inhibit osteoclasts [4, 24]. Therefore, regard-
less of whether bisphosphonates or anti-RANKL mAb are
used, osteoclast suppression delays osseous healing and
causes the retention of inflammation in the soft tissue.
The sustained inflammation could be sterile inflammation
caused by damage-associated molecular pattern molecules
from necrotic osteocytes [25] or pathogen-associated in-
flammation caused by locally infected bone. Although the
sustained inflammation was local, it may have a systemic
impact. It is possible that the elevated γδTCR(+) cells in
the bone marrow were associated with the sustained inflam-
mation in the oral wounds.
In summary, this study clearly shows that mouse anti-
RANKL mAb treatment increased bone mass by suppress-
ing osteoclasts. However, the anti-RANKL mAb treatment
resulted in increased TRAP(+) MNCs in bone marrow and
altered oral osseous wound healing. Osteoclastic repair of
the damaged palate was delayed and inflammation
sustained due to osteoclast suppression. Although the cur-
rent study used the mouse anti-RANKL mAb, findings
were comparable to those of a study where zoledronic acid
was used. Therefore, increased TRAP(+) MNCs are asso-
ciated with osteoclast suppression, not specifically
bisphosphonates or anti-RANKL mAb.
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